Capital Advisors Inc. OK Sells 439 Shares of Amgen Inc. (NASDAQ:AMGN)

Capital Advisors Inc. OK cut its holdings in shares of Amgen Inc. (NASDAQ:AMGN) by 17.1% during the 3rd quarter, HoldingsChannel reports. The institutional investor owned 2,126 shares of the medical research company’s stock after selling 439 shares during the period. Capital Advisors Inc. OK’s holdings in Amgen were worth $685,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of AMGN. Meyer Handelman Co. increased its holdings in Amgen by 7.2% during the second quarter. Meyer Handelman Co. now owns 129,831 shares of the medical research company’s stock worth $40,566,000 after buying an additional 8,700 shares during the last quarter. EP Wealth Advisors LLC raised its holdings in shares of Amgen by 11.0% in the 1st quarter. EP Wealth Advisors LLC now owns 23,769 shares of the medical research company’s stock valued at $6,758,000 after purchasing an additional 2,353 shares during the period. Stanley Laman Group Ltd. acquired a new stake in Amgen in the 2nd quarter valued at about $3,354,000. Verity & Verity LLC grew its holdings in Amgen by 2.7% during the second quarter. Verity & Verity LLC now owns 82,368 shares of the medical research company’s stock worth $25,736,000 after purchasing an additional 2,182 shares during the period. Finally, Matrix Asset Advisors Inc. NY increased its position in Amgen by 9.3% during the second quarter. Matrix Asset Advisors Inc. NY now owns 45,068 shares of the medical research company’s stock worth $14,081,000 after buying an additional 3,845 shares during the last quarter. 76.50% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

AMGN has been the subject of a number of recent analyst reports. Truist Financial cut Amgen from a “buy” rating to a “hold” rating and raised their price objective for the company from $320.00 to $333.00 in a research report on Monday, October 14th. UBS Group cut their price target on Amgen from $335.00 to $326.00 and set a “neutral” rating for the company in a report on Thursday. TD Cowen upped their price objective on shares of Amgen from $381.00 to $383.00 and gave the company a “buy” rating in a report on Monday, October 21st. Bank of America raised their target price on shares of Amgen from $325.00 to $330.00 and gave the stock a “neutral” rating in a research note on Wednesday, August 7th. Finally, Morgan Stanley decreased their price target on shares of Amgen from $310.00 to $303.00 and set an “equal weight” rating on the stock in a research note on Thursday, July 11th. One analyst has rated the stock with a sell rating, eleven have assigned a hold rating, eleven have given a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $333.50.

Amgen Price Performance

Shares of NASDAQ:AMGN opened at $319.22 on Friday. The firm has a 50 day moving average of $324.47 and a 200-day moving average of $315.54. Amgen Inc. has a 12 month low of $260.52 and a 12 month high of $346.85. The company has a current ratio of 1.26, a quick ratio of 0.89 and a debt-to-equity ratio of 9.64. The stock has a market capitalization of $171.53 billion, a PE ratio of 40.87, a PEG ratio of 2.84 and a beta of 0.61.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings data on Wednesday, October 30th. The medical research company reported $5.58 EPS for the quarter, beating the consensus estimate of $5.11 by $0.47. The business had revenue of $8.50 billion during the quarter, compared to the consensus estimate of $8.50 billion. Amgen had a net margin of 13.00% and a return on equity of 181.58%. The company’s revenue was up 23.2% on a year-over-year basis. During the same period in the previous year, the business earned $4.96 earnings per share. On average, equities research analysts predict that Amgen Inc. will post 19.48 EPS for the current fiscal year.

Amgen Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Monday, December 9th. Stockholders of record on Monday, November 18th will be issued a $2.25 dividend. The ex-dividend date is Monday, November 18th. This represents a $9.00 dividend on an annualized basis and a dividend yield of 2.82%. Amgen’s dividend payout ratio (DPR) is currently 115.24%.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.